Nebraska's Antrell Taylor wins wrestling national title after losing dad, brother to gun violence
Trump's crypto empire set to expand with new stablecoin and investment fund offerings
Teen recovering after suffering traumatic brain injury at track practice
Police help expecting mother deliver baby on highway
Ukraine railways say Sunday's cyber attack hit its online freight services
Secretive Chinese network tries to lure fired federal workers, research shows
Woman shares 'extremely terrifying' moment she says her car was hit by lightning
Trump has begun another trade war. Here's a timeline of how we got here
Coach breaks world record for run across Iowa
By Anne Kauranen
HELSINKI (Reuters) - Finnish drugmaker Orion wants to boost sales in the United States on the back of the success of its prostate cancer drug Nubeqa, which it is developing jointly with German partner Bayer, Orion's chief executive Liisa Hurme told Reuters.
The two companies announced on Thursday that sales of Nubeqa have been worth more than a billion euros this year, making it Orion's first "blockbuster" product, and that Bayer is seeking approval from U.S. authorities to expand its use to a new patient group.
Nubeqa, also known as darolutamide, is Bayer's third best selling drug globally with sales growing most rapidly in the U.S., Hurme said.
That encouraged Orion to establish a research centre in the U.S. last year, with an eye on growth opportunities in a country that accounts for roughly half of the world's drug market, Hurme said.
"We are in the U.S. in order to develop our own innovations in that market ourselves," she said, referring to Orion's ODM-111 molecule for pain treatment and Orion's cooperation with U.S. based drugmaker Merck & Co in the development of opevesostat, used against metastatic castration-resistant prostate cancer, among other products.
"Pain is highly undertreated and especially in the U.S., the use of opiates is a major problem," she added, referring to the expansion of drug misuse.
Bayer said it was submitting an application to the U.S. Food and Drug administration for a third indication for darolutamide to be used in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, following a successful phase III trial.
(Reporting by Anne Kauranen; Editing by Kirsten Donovan)
